Giada Bianchi, MD, discusses the scope of frontline therapy and subsequent maintenance strategies among patients with transplant eligible and ineligible newly diagnosed multiple myeloma.
Juan P. Alderuccio, MD, discusses the current state of the treatment paradigm in multiple myeloma and ongoing challenges that remain.
Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted positive opinions to 2 triplet regimens with immunomodulatory agents for patients with multiple myeloma.
A Type II variation application has been submitted to the European Medicines Agency for the 4-drug regimen of daratumumab, bortezomib, thalidomide, and dexamethasone as a treatment for patients with newly diagnosed multiple myeloma who are eligible to undergo autologous stem cell transplant.
A supplemental biologics license application has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
James E. Hoffman, MD, discusses the current treatment options available for patients with multiple myeloma, underscores remaining challenges in the space, and shares predictions for where the field is headed.
A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
The investigational antibody-drug conjugate GSK2857916 continued to improve progression-free survival in patients with relapsed/refractory multiple myeloma, according to results of a final analysis of the DREAMM-1 study.
The FDA has placed a partial clinical hold on all clinical trials examining venetoclax in multiple myeloma, halting enrollment of new patients on the studies.